Crispr Therapeutics shares tumble after significant earnings miss
Director Richard J. Salute of NewtekOne, Inc. (NASDAQ:NEWT), a company currently valued at $295 million and trading at an attractive P/E ratio of 5.8x, recently purchased a total of 2,100 shares of common stock in two transactions. The purchases, which occurred on August 1, 2025, were executed at prices ranging from $11.23 to $11.2499, totaling $23,610.
According to a Form 4 filing with the Securities and Exchange Commission, Salute acquired 700 shares at $11.23 and 1,400 shares at $11.2499. Following these transactions, Salute directly owns 43,605 shares of NewtekOne. The company maintains a notable 6.79% dividend yield and has consistently paid dividends for 11 consecutive years. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.
In other recent news, NewtekOne, Inc. reported its second-quarter 2025 financial results, revealing that earnings per share (EPS) met expectations at $0.52. However, the company’s revenue fell short of forecasts, recording $70.2 million compared to the anticipated $73.88 million. In addition to its financial performance, NewtekOne announced an expansion of its revolving credit facility with Capital One (NYSE:COF), N.A., increasing it from $60 million to $100 million and extending the maturity by two years. This expansion is aimed at funding the origination of Alternative Loan Program (ALP) loans before they are placed into securitizations. This development follows a similar expansion of the company’s Deutsche Bank (ETR:DBKGn) ALP facility earlier this year. These recent developments reflect NewtekOne’s efforts to enhance its financial resources and loan origination capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.